Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/2048872614554108 http://scihub22266oqcxt.onion/10.1177/2048872614554108 C4657388!4657388!25267878     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+Heart+J+Acute+Cardiovasc+Care 2015 ; 4 (6): 555-60 Nephropedia Template TP {{tp|p=25267878|t=2015. Dyspnoea management in acute coronary syndrome patients treated with ticagrelor |pdf=|usr=}}{{25267878}} gab.com Text Dyspnoea management in acute coronary syndrome patients treated with ticagrelor JO: Eur Heart J Acute Cardiovasc Care http://www.kidney.de/pget.php?&tw=1&pmid=25267878 #FOAvip The occurrence of dyspnoea in acute coronary syndrome (ACS) patients has always been considered a challenging diagnostic and therapeutic clinical scenario. P2Y12 platelet receptor inhibitors (i.e., clopidogrel, prasugrel and ticagrelor) are currently the cornerstone of treatment of ACS patients. Thus, in the last few years, the potential association between ACS and dyspnoea has also become more challenging with the increasing use of ticagrelor in these patients due to its beneficial effects on ischaemic event prevention and mortality, since ticagrelor can induce dyspnoea as a side effect. The present article is intended to review the current literature regarding dyspnoea occurrence in ACS patients, especially those treated with ticagrelor, and to propose ticagrelor-associated dyspnoea management recommendations based on current knowledge. Twit Text FOAVip Dyspnoea management in acute coronary syndrome patients treated with ticagrelor ????Eur Heart J Acute Cardiovasc Care http://www.kidney.de/pget.php?&tw=1&pmid=25267878 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25267878 #FOAvip English Wikipedia <ref>{{Cite pmid|25267878}}</ref> Dyspnoea management in acute coronary syndrome patients treated with ticagrelor #MMPMID25267878 Parodi G; Storey RF Eur Heart J Acute Cardiovasc Care 2015[Dec]; 4 (6): 555-60 PMID25267878show ga The occurrence of dyspnoea in acute coronary syndrome (ACS) patients has always been considered a challenging diagnostic and therapeutic clinical scenario. P2Y12 platelet receptor inhibitors (i.e., clopidogrel, prasugrel and ticagrelor) are currently the cornerstone of treatment of ACS patients. Thus, in the last few years, the potential association between ACS and dyspnoea has also become more challenging with the increasing use of ticagrelor in these patients due to its beneficial effects on ischaemic event prevention and mortality, since ticagrelor can induce dyspnoea as a side effect. The present article is intended to review the current literature regarding dyspnoea occurrence in ACS patients, especially those treated with ticagrelor, and to propose ticagrelor-associated dyspnoea management recommendations based on current knowledge. äDyspnoea management in acute coronary syndrome patients treated with t(epmc).pdf DeepDyve Pubget Overpricing